BioCryst Pharmaceuticals, Inc..
BCRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
BioCryst Pharmaceuticals, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of novel, oral medicines that treat rare diseases. The company's key products include ORLADEYO® (berotralstat), an oral therapy for hereditary angioedema (HAE) prophylaxis, and...Show More
Better Health for All
30
BioCryst Pharmaceuticals focuses on developing and commercializing oral therapies for rare diseases, including ORLADEYO, which is the first and only oral therapy for hereditary angioedema (HAE) prophylaxis in adults and pediatric patients 12 years and older.
1
The company is also developing a pediatric formulation for HAE.
2
The company provides important safety information for its products, detailing adverse reactions and dosage adjustments.
3
ORLADEYO is designed for prophylaxis.
4
The company utilizes a structure-guided drug design platform, integrating crystallography with traditional biology and medicinal chemistry.
5
BioCryst also operates an expanded access program for investigational medicines for serious or life-threatening conditions, and emphasizes clinical trial data transparency.
6
Fair Money & Economic Opportunity
0
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines. The company does not operate in the financial services sector and does not offer lending, deposit, or other financial products to consumers.
1
Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth-building outcomes, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its business model.
2
Fair Pay & Worker Respect
20
The company's CEO-to-median employee pay ratio for 2024 was 30:1, as reported in SEC proxy statements.
1
Fair Trade & Ethical Sourcing
0
The provided article, BioCryst UK Limited's Modern Slavery and Human Trafficking Statement for the financial year ending 31 December 2024, details a commitment to ethical sourcing and a safe work environment, emphasizing their Code of Conduct and Ethics.
1
However, it explicitly states that no quantitative data related to the specific metrics requested is provided.
2
Therefore, there is no evidence to score any of the KPIs for Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
BioCryst Pharmaceuticals has a comprehensive whistleblower policy that encourages employees to report concerns through multiple channels, including supervisors, HR, legal, corporate officers, an anonymous hotline, and an online portal.
1
Specific accounting or auditing concerns can be reported directly to the Chair of the Audit Committee, and the policy explicitly states no retaliation for good faith reports.
2
The company is subject to the U.S. Foreign Corrupt Practices Act (FCPA) and has an anti-corruption policy prohibiting bribery and kickbacks.
3
However, the articles do not provide details on the frequency or effectiveness metrics of its anti-corruption training programs, nor do they specify if the policy covers all international operations with customized guidance for high-risk areas.
Kind to Animals
0
BioCryst Pharmaceuticals conducts pre-clinical studies on animals to assess drug safety, including testing on monkeys for an experimental Ebola antiviral drug (BCX4430).
1
In these studies, treated animals showed significantly improved survival rates (80-100%) compared to placebo-treated animals (20-30%).
2
However, no specific data is provided regarding the company's animal testing policy, the volume of animals used, alternative testing methods, cruelty-free certifications, or any other animal welfare metrics.
3
No War, No Weapons
0
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on rare diseases.
1
The provided articles do not contain any evidence of the company being involved in arms manufacturing, military contracts, or conflict facilitation. There is no mention of revenue from arms or defense contracts, dual-use technologies with military applications, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' value.
2
The company's contract with HHS for RAPIVAB is for an antiviral drug for public health emergencies, not a military contract.
3
Therefore, all KPIs are scored as N/A, indicating no defense or arms-related activities in its core business or operations.
Planet-Friendly Business
0
No specific, quantitative, or actionable evidence was found in the provided articles to assess BioCryst Pharmaceuticals, Inc. against any of the 'Planet-Friendly Business' KPIs. The articles explicitly state a lack of specific sustainability data for the company, with mentions of general regulatory compliance and hazardous materials handling but no specific metrics or outcomes related to environmental performance.
1
An overall ESG risk rating was mentioned but contradicted within the same article and does not map to the specific quantitative KPIs in the rubric.
2
Respect for Cultures & Communities
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities'. Article 0 provides an overall ESG risk rating and employee count but no details on community engagement, cultural impact, or local economic contributions.
1
Article 1 discusses patient advocacy efforts, emphasizing partnerships with patient organizations and support for patient needs, but it does not offer quantitative data or specific actions relevant to the defined KPIs, such as formal partnerships with indigenous or local community groups, cultural appropriation incidents, or local employment ratios.
2
Safe & Smart Tech
20
BioCryst Pharmaceuticals has experienced cybersecurity threats and incidents, but none have had a material impact on its business, reputation, or financial condition.
1
The company requires all employees to undergo mandatory annual compliance training, including regular cybersecurity training, with records maintained and non-compliance leading to disciplinary action.
2
BioCryst transmits data using HTTPS and TLS.
3
Users have rights to access, correct, delete, restrict processing, object to processing, transfer data, and withdraw consent.
4
The company conducts regular system audits, third-party monitoring, vulnerability scanning, and penetration tests.
5
BioCryst retains personal information only as long as reasonably required for legal, contractual, or business purposes.
6
The company explicitly states adherence to and compliance with HIPAA, GDPR, and CPRA, and has appointed a Data Protection Officer.
7
Zero Waste & Sustainable Products
-10
BioCryst Pharmaceuticals demonstrates strong compliance with biohazardous waste treatment, achieving a 99.8% compliance rate.
1
The company has also achieved a 17.2% reduction in hazardous chemical waste.
2